RT-PCR Market is expected to reach US$ 4.47 Billion by 2031

Reagents & Consumables Segment based on the Product Drives RT-PCR Market Growth    

According to our new research study named "RT-PCR Market Forecast to 2031 – Global Analysis – by Product, Application, and End User," the market was valued at US$ 2.71 billion in 2024 and is projected to reach US$ 4.47 billion by 2031; it is expected to register a CAGR of 7.5% during 2025–2031. The surging global infectious disease outbreaks necessitating rapid diagnostic capabilities, escalating cancer incidence driving oncogene detection and personalized diagnostics, and advancing genetic testing for precision medicine and hereditary disorders are key factors driving the RT-PCR market size. However, high costs and limited accessibility of RT-PCR testing kits hinders market growth. The expansion in point-of-care RT-PCR for rapid infectious disease response is projected to bring new RT-PCR market trends in the coming years.         

Reverse Transcription Polymerase Chain Reaction (RT-PCR) is a laboratory technique used to detect and measure RNA by converting it into complementary DNA (cDNA) through reverse transcription, followed by amplification using PCR. It is widely used for viral detection, gene expression analysis, and molecular diagnostics because of its high sensitivity and specificity. RT-PCR played a critical role during the COVID-19 pandemic for identifying SARS-CoV-2 infections. The technique enables early disease detection, monitoring of viral load, and research into genetic activity, making it an essential tool in clinical diagnostics, biomedical research, and public health surveillance worldwide.   

RT-PCR Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

RT-PCR Market Analysis Based on Segmental Evaluation: 

• Based on product, the RT-PCR market is categorized into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest RT-PCR market share in 2024. The reagents and consumables segment is growing because RT-PCR testing requires repeated purchases of kits and enzymes.
• Based on applications, the RT-PCR market is segmented into research application, clinical application, and forensic application. The clinical applications segment held a significant RT-PCR market share in 2024. The clinical application segment is growing due to rising demand for accurate molecular diagnostics in infectious diseases, oncology, genetic testing, and routine hospital laboratory testing worldwide. The clinical application segment is sub-segmented into oncology testing, blood screening, infectious disease testing, and other applications. 
• Based on end user, the RT-PCR market is divided into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held the largest RT-PCR market share in 2024. Hospitals and diagnostic centers dominate the RT-PCR market because they perform high-volume clinical diagnostics for infectious and genetic diseases, have advanced lab infrastructure, and require fast, accurate test results for patient care and treatment decisions.   

The geographical scope of the RT-PCR market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. The North America RT-PCR market is propelled by the ongoing demand for rapid and accurate diagnostic testing, especially highlighted by recent infectious disease outbreaks. In the US, the CDC reported over 120 million COVID-19 cases by 2022, emphasizing the crucial role of RT-PCR testing in managing the pandemic. According to the CDC and FDA reports, the prevalence of COVID-19 continued to influence testing strategies in 2023 and 2024, with estimates indicating that millions of tests were conducted monthly to monitor and control the virus's spread. Additionally, the increasing incidence of other infectious diseases, such as influenza and respiratory syncytial virus (RSV), has further boosted testing demand.

The RT-PCR market outlook indicates that Asia Pacific is expected to register the fastest growth in the coming years, supported by increasing incidence of infectious diseases and advancements in diagnostic technologies. According to the World Health Organization (WHO), the region reported nearly 700 million cases of infectious diseases in 2022, with projections indicating continued upward trends due to urbanization and population density, especially in countries such as India and China. In India, the Ministry of Health and Family Welfare reported over 200,000 new COVID-19 cases in early 2023, underlining the ongoing demand for effective diagnostic solutions. By 2024, the requirement for RT-PCR testing is expected to persist, particularly as respiratory infections continue to pose significant health challenges. 

Abbott, Qiagen, Bio-Rad Laboratories Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., GE Healthcare, bioMérieux, F. Hoffmann-La Roche Ltd, Takara Bio Inc., and Genome Diagnostics Pvt Ltd are among the leading companies profiled in the RT-PCR market report.  

Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).  

Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com